Efficacy of Tocilizumab vs. NSAIDs in the Treatment of Juvenile Rheumatoid Arthritis
Journal Title: International Journal Of Medical Science And Clinical Research Studies - Year 2022, Vol 2, Issue 04
Abstract
Tocilizumab is a humanized monoclonal antibody that binds to IL-6 receptors, both the soluble receptor (sIL-6R) and the one located in the cell membrane. In this way it blocks the molecular complex of the receptor and prevents cytokine signaling. It is a drug which has recently been approved by the FDA, several studies recently carried out at international level (USA, Japan, Europe) have demonstrated the great efficacy of tocilizumab in the treatment of juvenile rheumatoid arthritis.
Authors and Affiliations
Daniela I. Sánchez, Paola L. Padilla, Felix Osuna Gutierrez, Giancarlo T. Ornelasa, Flavio Humberto Ávalos
Keywords
Related Articles
- EP ID EP713747
- DOI 10.47191/ijmscrs/v2-i4-02
- Views 45
- Downloads 0
COVID-19 Vaccination Acceptance among Healthcare Staff in the West of Libya
Healthcare workers (HCWs) are vital in providing guidance and recommendations to patients and the wider community about vaccination, which includes giving correct information on the risks and benefits of the...
Chest Computed Tomography and Severity Markers in COVID-19
Background: Computed Tomography chest scan is a tool for classification of COVID 19 disease. We propose there is a relation between computed tomography severity index and inflammation biomarkers. Methods: We perform...
Diagnosis and Treatment of Pyelonephritis During Pregnancy
Urinary tract infections are the most common infections in pregnant women. The most common are asymptomatic bacteriuria, cystitis and pyelonephritis, the latter presenting as a complication in 1 to 2% of women. Urolith...
COVID-19, A New Outlook on Pandemic Symptoms and Diagnostic Approach
Background: The main objective of this research is to learn the symptoms that occur in this pathology, since we are currently still fighting COVID-19, because of this, it is important to keep us informed about the differ...
Breakthrough infections due to SARS-CoV-2 Wild type, the Delta variant and the Omicron variant in early fourth wave of epidemics in Myanmar
The “severe acute respiratory syndrome coronavirus type 2” (SARS-CoV-2) is also known as “coronavirus disease 19” (COVID-19). It originated in Wuhan, Hubei province, People’s Republic of China, in December 2019; and, it...